Traditional antiviral development struggles with high costs, slow innovation cycles, and unpredictable efficacy. Our research highlights a groundbreaking alternative: repurposing a harmless avian vaccine virus as a versatile, off-the-shelf antiviral tool.

Investment Potential

• Market Opportunity: The global antiviral market is projected to exceed $75 billion by 2030, driven by persistent viral threats and emerging pandemics. A safe, scalable viral-based therapy positions itself as a next-generation solution, addressing gaps in conventional treatments.
• Scalability & Cost Efficiency: Our viral-based therapy can be produced efficiently and at scale, reducing research & development timelines while ensuring broad accessibility.
• Regulatory & Safety Advantages: The use of an already approved vaccine virus streamlines regulatory approval, potentially leading to faster market entry and lower clinical trial risks.
• Competitive Edge: The approach offers a paradigm shift in antiviral treatment, differentiating itself from conventional small-molecule drugs and costly biologics.

Strategic Appeal

Investors focused on biotech innovation and disruptive health technologies will recognize the transformative potential of virus-driven antivirals—a sector poised for rapid growth.